NCT03936491View on ClinicalTrials.gov

The Neuroprotective Effects of Methylphenidate and Atomoxetine in Children With ADHD: A Lipidomic Study

NACompletedINTERVENTIONAL
Enrollment

105

Participants

Timeline

Start Date

August 1, 2019

Primary Completion Date

January 25, 2021

Study Completion Date

January 25, 2021

Conditions
Attention Deficit Hyperactivity Disorder
Interventions
DRUG

Methylphenidate

Methylphenidate is a central nervous system stimulant used for the therapy of attention deficit disorder and narcolepsy.

DRUG

Atomoxetine

Atomoxetine is a medication used to treat attention deficit hyperactivity disorder (ADHD).\[6\] Use is only recommended in those who are at least six years old.\[6\] It is taken by mouth.\[6\]

Trial Locations (1)

110

National Taiwan University Hospital, Taipei

All Listed Sponsors
lead

National Taiwan University Hospital

OTHER

NCT03936491 - The Neuroprotective Effects of Methylphenidate and Atomoxetine in Children With ADHD: A Lipidomic Study | Biotech Hunter | Biotech Hunter